Abstracts tagged "Health Assessment Questionnaire"

Abstract Number: 1370 • 2019 ACR/ARP Annual Meeting
Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)
Jing Yang¹, Zhenbiao Wu ², Yongfu Wang ³, Hua Wei ⁴, Yu Zhang ¹, Xiaoling Liu ⁵, Xiaofeng Rong ⁶, Jinmei Zou ¹, Xiaofei Shi ⁷, Hongbin Li ⁸, Rui Wu ⁹, Xiaoli Deng ¹⁰, Huiqiong Zhou ¹¹, Yuan Jia ¹², Wei Zhao ¹³, Shi Chen ¹², Xuewu Zhang ¹², Yingnan Li ¹⁴, Yingkun Nie ¹⁴, Yifang Mei ¹⁵, Jianyu Zhang ¹⁶, Hanyou Mo ¹⁷, li Sun ¹⁸, Yanfei Chen ¹⁹, Haili Shen ²⁰, Dongsheng Li ²¹, Yonggang Zhao ²², Hui Xiao ²³, Bing Wu ²⁴, Yuhua Jia ²² and Fei Xiao ²⁵, ¹Central Hospital of MianYang, Mianyang, Sichuan, China (People's Republic), ²The First Affiliated Hospital of The Fourth Military Medical University, Xian, Shanxi, China (People's Republic), ³The First Affiliated Hospital of BaoTou Medical College, Baotou, Nei Mongol, China (People's Republic), ⁴Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ⁵The 1st Affiliated Hospital of Guangzhou University of TCM, Guangzhou, China (People's Republic), ⁶The 1st Affiliated hospital of Chongqing medical University, Chongqing, Chongqing, China (People's Republic), ⁷First Affiliated Hospital of Henan University of Science and Technology, luoyang, Henan, China (People's Republic), ⁸The Affiliated Hospital of Inner Mongolia Medical University, Huhhot, Nei Mongol, China (People's Republic), ⁹The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China (People's Republic), ¹⁰Peking University Third Hospital, Beijing, Beijing, China (People's Republic), ¹¹Fourth Medical Center of PLA Genal Hospital, Beijing, Beijing, China (People's Republic), ¹²Peking University People's Hospital, Beijing, Beijing, China (People's Republic), ¹³Chinese PLA General Hospital, Beijing, Beijing, China (People's Republic), ¹⁴The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (People's Republic), ¹⁵The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (People's Republic), ¹⁶The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China (People's Republic), ¹⁷Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China (People's Republic), ¹⁸The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China (People's Republic), ¹⁹The First Hospital of Lanzhou University, Lanzhou, Gansu, China (People's Republic), ²⁰The Second Hospital of Lanzhou University, Lanzhou, Gansu, China (People's Republic), ²¹Ganzhou People's Hospital, Ganzhou, Jiangxi, China (People's Republic), ²²Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ²³Shanghai Gothic Internet Technology Co., Ltd, shanghai, Shanghai, China (People's Republic), ²⁴Shanghai Gothic Internet Technology Co., Ltd, Shanghai, China (People's Republic), ²⁵Shanghai Gothic Internet Technology Co., Ltd., shanghai, China (People's Republic)
Background/Purpose: Treat to target (T2T), achieving a DAS28 score lower than 3.2, is the strategy recommended by ACR and EULAR. Health assessment questionnaire (HAQ) is…
Abstract Number: 223 • 2018 ACR/ARHP Annual Meeting
The Effect of Concomitant Diabetes on RA-Related Outcomes: Results from the Acr’s RISE Registry
Huifeng Yun¹, Fenglong Xie¹, Lang Chen¹, Shuo Yang¹, Leticia Ferri², Evo Alemao², Tammy Curtice² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The impact of concomitant comorbidities on RA outcomes is of high interest, and some evidence suggests that patients (pts) with RA and diabetes may…
Abstract Number: 332 • 2018 ACR/ARHP Annual Meeting
Components of Impaired Physical Function and Disability in a Non-Rheumatic Population. Normative Values of the Health Assessment Questionnaire Disability Index
C Alejandro Arce-Salinas¹, H FABRICIO ESPINOSA-ORTEGA² and Olivia Enriquez-Antonio³, ¹INTERNAL MEDICINE, Hospital Central Sur PEMEX, MEXICO, Mexico, ²Rheumatology Department, Karolinska Universitetssjukhuset, Stockolm, Sweden, ³Internal Medicine, Hospital Central Sur PEMEX, mexico, Mexico
Background/Purpose: HAQ-Di is broadly used to measure disability in RA, its assessment might influence taking decision process. However, it cannot differentiate disability related to arthritis,…
Abstract Number: 335 • 2018 ACR/ARHP Annual Meeting
Cross-Cultural Validity of Functional Status Assessment Measures for Rheumatoid Arthritis
Stephanie Kulhawy-Wibe¹, JoAnn Zell^2,3, Kaleb Michaud⁴, Jinoos Yazdany⁵, Linda S. Ehrlich-Jones^6,7, Carter Thorne⁸, Donna Everix⁹ and Claire Barber¹⁰, ¹University of Calgary, Calgary, AB, Canada, ²Denver Health, Denver, CO, ³University of Colorado, Denver, CO, ⁴Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵University of California, San Francisco, San Francisco, CA, ⁶Shirley Ryan AbilityLab, Chicago, IL, ⁷Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸University of Toronto, Newmarket, ON, Canada, ⁹OnMyCare Home Health, Fremont, CA, ¹⁰Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Functional Status Assessment Measures (FSAMs) are important outcome measures in Rheumatoid Arthritis (RA) as poor function is a predictor for mortality and associated with…
Abstract Number: 1434 • 2018 ACR/ARHP Annual Meeting
Patient-Proxy Agreement on Health-Related Quality of Life in Juvenile Fibromyalgia Syndrome
Sabrina Gmuca, Audrey Urquhart and David D. Sherry, Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The administration of proxy-reported health-related quality of life (HRQoL) measures in the assessment of juvenile fibromyalgia syndrome (JFMS) is common but its added clinical…
Abstract Number: 1533 • 2018 ACR/ARHP Annual Meeting
Simulating Population Disability Outcomes for Alternative Treatment Pathways in Patients with Active Rheumatoid Arthritis
Josephine Mauskopf¹, Mahdi Gharaibeh², David Wamble¹, David H. Collier², Bradley S. Stolshek² and Eric L. Matteson³, ¹RTI Health Solutions, Research Triangle Park, NC, ²Amgen Inc., Thousand Oaks, CA, ³Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that causes joint pain and swelling, bone erosions, and deformity. This debilitating disease can severely…
Abstract Number: 1600 • 2018 ACR/ARHP Annual Meeting
Psychometric Properties of the Assessment of Spa International Society Health Index in Patients with Active As/Radiographic Axial Spa in a Phase 3 Clinical Study
Uta Kiltz¹, Désirée van der Heijde², Annelies Boonen^3,4, Lianne S. Gensler⁵, Theresa Hunter⁶, Yan Dong⁶, Kathleen Wyrwich⁶, Hilde Carlier⁶ and Jürgen Braun^1,7, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Leiden University Medical Centre, Leiden, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Caphri Research Institute, Maastricht, Netherlands, ⁵University of California San Francisco, San Francisco, CA, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Ruhr Universität Bochum, Bochum, Germany
Background/Purpose: The Assessment of SpA international Society Health Index (ASAS HI) was developed to assess function, disability, and health in patients (pts) with SpA. This…
Abstract Number: 1865 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Significantly Improves Self-Reported Overall Functioning and Health in Patients with Active As/Radiographic Axial Spa Naive to Biologic DMARD Therapy: 16‑Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial
Uta Kiltz¹, Désirée van der Heijde², Annelies Boonen^3,4, Lianne S. Gensler⁵, Theresa Hunter⁶, Fangyi Zhao⁶, Hilde Carlier⁶ and Jürgen Braun^1,7, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Leiden University Medical Centre, Leiden, Netherlands, ³Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Caphri Research Institute, Maastricht, Netherlands, ⁵School of Medicine, UCSF, San Francisco, CA, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Ruhr Universität Bochum, Bochum, Germany
Background/Purpose: The Assessment of SpA international Society Health Index (ASAS HI) is a relatively new measure to assess function, disability, and health in patients with…
Abstract Number: 1923 • 2018 ACR/ARHP Annual Meeting
Treating Rheumatoid Arthritis to Target: Is Low Disease Activity Good Enough?
Elena Nikiphorou¹, Sam Norton², Adam Young³, Lewis Carpenter², Josh Dixey⁴, David Walsh⁵ and Patrick Kiely⁶, ¹Academic Rheumatology, Department of Inflammation Biology, King's College London, London, Great Britain, ²Academic Rheumatology, King's College London, London, United Kingdom, ³University of Hertfordshire, Hertford, United Kingdom, ⁴Rheumatology, The Royal Wolverhampton, Wolverhampton, United Kingdom, ⁵Academic Rheumatology, University of Nottingham, Nottingham, Great Britain, ⁶Rheumatology Dept, St Georges Hospital, London, Great Britain
Treating Rheumatoid Arthritis To Target: Is Low Disease Activity Good Enough? Background/Purpose: It is now widely recognised that treat-to-target (T2T) principles in rheumatoid arthritis (RA)…
Abstract Number: 2491 • 2018 ACR/ARHP Annual Meeting
Treat-to-Target (T2T) Is Not Enough: Identify Factors Leading to a Mismatch between T2T and HAQ Among RA Patients through Data Mining from Smart System of Disease Management (SSDM)
Jing Yang¹, Hua Wei², Jianlin Huang³, Wenqiang Fan⁴, Hongzhi Wang⁵, Yongfu Wang⁶, Rong Mu⁷, Chun Li⁸, Jinmei Zou¹, Yu Zhang¹, Bin Wu⁹, Jianling Dong¹, Xiaofei Shi¹⁰, Xinwang Duan¹¹, Jianhong Wu¹², Fang He¹³, Hong Liu¹, Zhijun Li¹⁴, Guosheng Wang¹⁵, Shengguang Li¹⁶, Bei Wang¹⁷, Yanjie Hao¹⁸, Huiqiong Zhou¹⁹, Haili shen²⁰, Yang Cui²¹, Wenhui Huang²², Qing-chun Huang²³, Hui Xiao²⁴, Yuhua Jia²⁴, Fei Xiao²⁴ and Feng-Chun Zhang²⁵, ¹Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ²Northern Jiangsu People's Hospital, Yangzhou, China, ³Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵The First Hospital of Jiaxing, Jiaxing, China, ⁶The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁷Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁸Peking University People's Hospital, Beijing, China, ⁹Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, ¹⁰The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹¹Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹²Dazhou Central Hospital, Dazhou, China, ¹³Central Hospital of Sui Ning, Sichuan, Suining, China, ¹⁴The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁵Department of rheumatology, Anhui Medical University Affiliated Provincial Hospital, Hefei, China, ¹⁶Peking University International Hospital, Beijing, China, ¹⁷Beijing Hospital of Traditional Chinese Medicine (TCM), Beijing, China, ¹⁸The First Affiliated Hospital of Beijing University, Beijing, China, ¹⁹The First Affiliated Hospital of PLA General Hospital, Beijing, China, ²⁰Department of Rheumatology and Immunology, Second Hospital of Lanzhou University, lanzhou, China, ²¹Guangdong General Hospital, Guangzhou, China, ²²The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, ²³Rheumatology, Guangzhou Provincial Hospital of Traditional Chinese Medicine, Guangzhou, China, ²⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁵Peking Union Medical College Hospital, Beijing, China
Background/Purpose: T2T, achieving a DAS28 score lower than 3.2 is the main management strategy recommended by ACR and EULAR. HAQ is the most widely used…
Abstract Number: 2492 • 2018 ACR/ARHP Annual Meeting
Pattern Shift and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Rong Mu¹, Chun Li², Jing Yang³, Hua Wei⁴, Jianlin Huang⁵, Wenqiang Fan⁶, Yongfu Wang⁷, Hongzhi Wang⁸, Jinmei Zou³, Xiaofei Shi⁹, Xiafei Xin¹⁰, Jianhong Wu¹¹, Fen Li¹², Shouxin Li¹³, Huiqin Yang¹⁴, Anbing Zhang¹⁵, Dongbao Zhao¹⁶, Jinchang He¹⁷, Junli Zhang¹⁸, Luo Li¹⁹, Peng Ji²⁰, Xiaofeng Rong²¹, Feng Jiang²², Ling Wang²³, Yuhua Jia²⁴, Fei Xiao²⁴ and Zhan-Guo Li²⁵, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Peking University People's Hospital, Beijing, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Northern Jiangsu People's Hospital, Yangzhou, China, ⁵Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁶Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁷The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁸The First Hospital of Jiaxing, Jiaxing, China, ⁹The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹⁰Ningbo First Hospital, Zhejiang, Ningbo, China, ¹¹Dazhou Central Hospital, Dazhou, China, ¹²The Second Xiangya Hospital of Central South University, Changsha, China, ¹³Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology, wuhan, China, ¹⁴Wuhan No 1 Hospital, wuhan, China, ¹⁵Xiangyang Central Hospital, Xiangyang, China, ¹⁶Changhai Hospital of Shanghai, Shanghai, China, ¹⁷PanZhiHua Central Hospital, Panzhihua, China, ¹⁸Xi 'an no.5 hospital, Xian, China, ¹⁹The First Affiliated Hospital of XinJiang Medical University, Wulumuqi, China, ²⁰[email protected], Wulumuqi, China, ²¹Affiliated hospital of Chongqing medical University, Chongqing, China, ²²Huzhou Third People's Hospital, Huzhou, China, ²³Zao Zhuang Municipal Hospital, zaozhuang, China, ²⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁵Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Treat-to-Target (T2T), achieving a DAS28 score lower than 2.6 (remission, Rem) or below 3.2 (low disease activity, LDA), is the main management strategy recommended…
Abstract Number: 2687 • 2018 ACR/ARHP Annual Meeting
Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors
Vivek Nagaraja¹, John Powers², Celia J. F. Lin³, Benjamin Brennan⁴, Veronica J. Berrocal⁵ and Dinesh Khanna¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Maryland School of Medicine, Rockville, MD, ³Genentech, Inc., South San Francisco, CA, ⁴School of Public Health, University of Michigan, Ann Arbor, MI, ⁵Div of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment benefit is demonstrated by evidence that interventions have positive impacts on how patients feel, function, and/or survive (FDA Guidance, 21CFR314.510). The ACR CRISS,…
Abstract Number: 2242 • 2017 ACR/ARHP Annual Meeting
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Rong Mu¹, Jing Yang², Hua Wei³, Wenqiang Fan⁴, Jianlin Huang⁵, Hongzhi Wang⁶, Jinli Ru⁷, Yongfu Wang⁸, Jinmei Zou², Jianling Dong², Xinwang Duan⁹, Fang He¹⁰, Xiaofei Shi¹¹, Xiafei Xin¹², Fei Xiao¹³, Hui Xiao¹³, Yuhua Jia¹³, Minjun Wang¹³, Lijun He¹³, Rui Bai¹³, Xiyao Huang¹³, Bing Wu¹³ and Zhanguo Li¹⁴, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ³No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁶The First Hospital of Jiaxing, Jiaxing, China, ⁷The 264th Hospital of the PLA, Taiyuan, China, ⁸The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁹Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹⁰Central Hospital of Sui Ning, Sichuan, Suining, China, ¹¹The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹²Ningbo First Hospital, Zhejiang, Ningbo, China, ¹³Gothic Internet Technology Corporation, Shanghai, China, ¹⁴Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Treat-to-Target (T2T), achieving a DAS28 lower than 2.6 (remission) or below 3.2 (low disease activity), is the main management strategy. The Smart System of…
Abstract Number: 2244 • 2017 ACR/ARHP Annual Meeting
Can Achieving Remission Improve Work Ability and Quality of Life in Early Rheumatoid Arthritis (RA) Patients? a Prospective Cohort Study
Ho Man Lam¹, Tsz Ho CHENG² and Lai-Shan Tam¹, ¹Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: RA patients often suffer from impaired work ability and reduced health related quality of life (HRQoL). Whether achieving remission through tight-control treatment strategy using…
Abstract Number: 2245 • 2017 ACR/ARHP Annual Meeting
The Effects of Structural Damage on Functional Disability in Psoriatic Arthritis
Andreas Kerschbaumer¹, Gabriela Supp¹, Josef S. Smolen^1,2 and Daniel Aletaha¹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
Background/Purpose: Functional outcomes are central in patients with chronic inflammatory musculoskeletal diseases. In a secondary data analysis of the GO-REVEAL trial we investigated if structural…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].